PubMed

Apoptosis: a clinical perspective.

Borden EC, Kluger H, Crowley J.

Nat Rev Drug Discov. 2008 Dec;7(12):959. No abstract available. PMID: 19065702 [PubMed - indexed for MEDLINE]Related articles

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

J Clin Oncol. 2008 Nov 20;26(33):5360-7. Epub 2008 Oct 27.PMID: 18955451 [PubMed - indexed for MEDLINE]Related articlesFree article

Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.

Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2008 Dec;28(12):733-40.PMID: 18937547 [PubMed - indexed for MEDLINE]Related articles

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.

J Clin Oncol. 2008 Feb 1;26(4):626-32.PMID: 18235122 [PubMed - indexed for MEDLINE]Related articles

Melanoma 2007: current state and preview of the future.

Borden EC.

Semin Oncol. 2007 Dec;34(6):449-51. No abstract available. PMID: 18083367 [PubMed - indexed for MEDLINE]Related articles

Interferons at age 50: past, current and future impact on biomedicine.

Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR.

Nat Rev Drug Discov. 2007 Dec;6(12):975-90. Review.PMID: 18049472 [PubMed - indexed for MEDLINE]Related articlesFree article

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC.

Lung Cancer. 2008 May;60(2):259-63. Epub 2007 Nov 19.PMID: 18006112 [PubMed - indexed for MEDLINE]Related articlesFree article

G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC.

J Clin Invest. 2007 Oct;117(10):3107-17.PMID: 17823654 [PubMed - indexed for MEDLINE]Related articlesFree article

Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.

Borden EC.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):491-501. Epub 2007 Aug 6. Review.PMID: 17689283 [PubMed - indexed for MEDLINE]Related articlesFree article

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.

Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC.

Oncogene. 2008 Jan 17;27(4):490-8. Epub 2007 Jul 23.PMID: 17653094 [PubMed - indexed for MEDLINE]Related articles

Intimal pulmonary artery sarcoma presenting as dyspnea: case report.

Hsing JM, Thakkar SG, Borden EC, Budd GT.

Int Semin Surg Oncol. 2007 Jun 29;4:14.PMID: 17603895 [PubMed]Related articlesFree article

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.

Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC.

J Clin Oncol. 2007 Jun 10;25(17):2406-13.PMID: 17557954 [PubMed - indexed for MEDLINE]Related articles

Adult sarcomas: a missed opportunity for sustained cooperative group translational and clinical research.

Borden EC.

Oncology (Williston Park). 2007 Feb;21(2):247-9. Review.PMID: 17396485 [PubMed - indexed for MEDLINE]Related articles

Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.

Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, Faber P, Bukowski R, Tong K, Borden EC.

Clin Pharmacol Ther. 2007 Mar;81(3):354-61.PMID: 17339865 [PubMed - indexed for MEDLINE]Related articles

Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.

Thakkar SG, Peereboom D, Olencki T, Jacobs B, Elson P, Rybicki L, Lindner DJ, Borden EC.

J Interferon Cytokine Res. 2006 Nov;26(11):800-3.PMID: 17115898 [PubMed - indexed for MEDLINE]Related articles

Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.

Li J, Lindner DJ, Farver C, Borden EC, Yi T.

Cancer Chemother Pharmacol. 2007 Aug;60(3):341-9. Epub 2006 Nov 14.PMID: 17103170 [PubMed - indexed for MEDLINE]Related articles

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC.

J Clin Oncol. 2006 Aug 10;24(23):3771-9. Epub 2006 Jun 26.PMID: 16801630 [PubMed - indexed for MEDLINE]Related articles

IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas.

Taylor KL, Oates RK, Grane R, Leaman DW, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2006 May;26(5):353-61.PMID: 16689662 [PubMed - indexed for MEDLINE]Related articles

Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer.

Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF.

Br J Cancer. 2006 May 22;94(10):1465-71.PMID: 16641915 [PubMed - indexed for MEDLINE]Related articlesFree article

Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.

Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC.

Cancer Res. 2006 Mar 1;66(5):2785-93.PMID: 16510600 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.

Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A.

Am J Clin Oncol. 2006 Feb;29(1):59-61.PMID: 16462504 [PubMed - indexed for MEDLINE]Related articles

Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.

Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, Borden EC, Yi T.

J Immunol. 2005 Nov 15;175(10):7003-8.PMID: 16272361 [PubMed - indexed for MEDLINE]Related articlesFree article

Review: Milstein Award lecture: interferons and cancer: where from here?

Borden EC.

J Interferon Cytokine Res. 2005 Sep;25(9):511-27.PMID: 16181052 [PubMed - indexed for MEDLINE]Related articles

Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.

Giannakopoulos NV, Luo JK, Papov V, Zou W, Lenschow DJ, Jacobs BS, Borden EC, Li J, Virgin HW, Zhang DE.

Biochem Biophys Res Commun. 2005 Oct 21;336(2):496-506.PMID: 16139798 [PubMed - indexed for MEDLINE]Related articles

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC.

Mol Cancer Ther. 2005 Jun;4(6):948-55.PMID: 15956252 [PubMed - indexed for MEDLINE]Related articlesFree article

Metastatic uveal melanoma.

Singh AD, Borden EC.

Ophthalmol Clin North Am. 2005 Mar;18(1):143-50, ix. Review.PMID: 15763199 [PubMed - indexed for MEDLINE]Related articles

Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.

Kelley TW, Borden EC, Goldblum JR.

Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):338-41.PMID: 15536333 [PubMed - indexed for MEDLINE]Related articles

Reverse signaling through membrane-bound interleukin-15.

Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, Bulfone-Paus S.

J Biol Chem. 2004 Oct 1;279(40):42192-201. Epub 2004 Jul 28.PMID: 15284244 [PubMed - indexed for MEDLINE]Related articlesFree article

Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).

Budagian V, Bulanova E, Orinska Z, Ludwig A, Rose-John S, Saftig P, Borden EC, Bulfone-Paus S.

J Biol Chem. 2004 Sep 24;279(39):40368-75. Epub 2004 Jun 23.PMID: 15215246 [PubMed - indexed for MEDLINE]Related articlesFree article

Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells.

Cui XF, Imaizumi T, Yoshida H, Borden EC, Satoh K.

Biochem Cell Biol. 2004 Jun;82(3):401-5.PMID: 15181474 [PubMed - indexed for MEDLINE]Related articles

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.

Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC.

Cell Death Differ. 2004 Aug;11(8):915-23.PMID: 15118763 [PubMed - indexed for MEDLINE]Related articlesFree article

Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.

Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A, Yi T, Williams BR, Borden EC.

J Interferon Cytokine Res. 2003 Dec;23(12):745-56.PMID: 14769151 [PubMed - indexed for MEDLINE]Related articles

Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.

Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ.

J Biol Chem. 2003 Oct 10;278(41):39461-9. Epub 2003 Jul 24.PMID: 12881518 [PubMed - indexed for MEDLINE]Related articlesFree article

Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.

Vyas K, Brassard DL, DeLorenzo MM, Sun Y, Grace MJ, Borden EC, Leaman DW.

J Immunother. 2003 May-Jun;26(3):202-11.PMID: 12806274 [PubMed - indexed for MEDLINE]Related articles

Soft tissue sarcomas of adults: state of the translational science.

Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF.

Clin Cancer Res. 2003 Jun;9(6):1941-56. Review.PMID: 12796356 [PubMed - indexed for MEDLINE]Related articlesFree article

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC.

Apoptosis. 2003 Jun;8(3):237-49. Review.PMID: 12766484 [PubMed - indexed for MEDLINE]Related articles

IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.

Bauer JA, Morrison BH, Grane RW, Jacobs BS, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2003 Jan;23(1):3-10.PMID: 12639293 [PubMed - indexed for MEDLINE]Related articles

New and modified interferon alfas: preclinical and clinical data.

Masci P, Bukowski RM, Patten PA, Osborn BL, Borden EC.

Curr Oncol Rep. 2003 Mar;5(2):108-13. Review.PMID: 12583827 [PubMed - indexed for MEDLINE]Related articles

High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction.

Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE.

J Biol Chem. 2003 May 9;278(19):16608-13. Epub 2003 Feb 11.PMID: 12582176 [PubMed - indexed for MEDLINE]Related articlesFree article

Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.

Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T.

Mol Cancer Ther. 2002 Dec;1(14):1255-64.PMID: 12516958 [PubMed - indexed for MEDLINE]Related articlesFree article

Anticancer activity of sodium stibogluconate in synergy with IFNs.

Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC.

J Immunol. 2002 Nov 15;169(10):5978-85.PMID: 12421984 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular characterization of soft tissue tumors.

Borden EC, Goldblum JR.

Curr Oncol Rep. 2002 Nov;4(6):497-8. No abstract available. PMID: 12354361 [PubMed - indexed for MEDLINE]Related articles

Malignant melanoma: treatments emerging, but early detection is still key.

Masci P, Borden EC.

Cleve Clin J Med. 2002 Jul;69(7):529, 533-4, 536-8 passim. Review.PMID: 12109636 [PubMed - indexed for MEDLINE]Related articlesFree article

IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.

Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC.

J Immunol. 2002 Jul 15;169(2):847-55.PMID: 12097388 [PubMed - indexed for MEDLINE]Related articlesFree article

Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells.

Padovan E, Terracciano L, Certa U, Jacobs B, Reschner A, Bolli M, Spagnoli GC, Borden EC, Heberer M.

Cancer Res. 2002 Jun 15;62(12):3453-8.PMID: 12067988 [PubMed - indexed for MEDLINE]Related articlesFree article

Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).

Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC.

J Interferon Cytokine Res. 2002 May;22(5):603-13.PMID: 12060499 [PubMed - indexed for MEDLINE]Related articles

Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.

Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S, Borden EC.

J Biol Chem. 2002 Aug 9;277(32):28504-11. Epub 2002 May 23.PMID: 12029096 [PubMed - indexed for MEDLINE]Related articlesFree article

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.

Smalley RV, Weller E, Hawkins MJ, Oken MM, O'Connell MJ, Haase-Statz S, Borden EC.

Leukemia. 2001 Jul;15(7):1118-22.PMID: 11455982 [PubMed - indexed for MEDLINE]Related articles

Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.

Chawla-Sarkar M, Leaman DW, Borden EC.

Clin Cancer Res. 2001 Jun;7(6):1821-31.PMID: 11410525 [PubMed - indexed for MEDLINE]Related articlesFree article

Melanoma and pregnancy.

Borden EC.

Semin Oncol. 2000 Dec;27(6):654-6.PMID: 11130472 [PubMed - indexed for MEDLINE]Related articles